Myriad Genetics Inc MYGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Myriad Genetics Reports Third Quarter 2026 Financial Results; Raises Mid-Point of Full-Year 2026 Revenue Guidance Following Solid Execution Definitive Agreement to Sell Prenatal Health Business to Support Strategic Growth Initiatives
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology
Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
Trading Information
- Previous Close Price
- $5.67
- Day Range
- $5.57–5.85
- 52-Week Range
- $2.74–8.08
- Bid/Ask
- $5.68 / $5.69
- Shares Outstanding
- 95.92M
- Market Cap
- $545.32M
- Volume/Avg
- 817,547 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 4,693.71
- Price/Sales
- 0.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 2,700
- Website
- https://www.myriad.com
Valuation
Metric | MYGN |
|---|---|
Price/Earnings (Normalized) | 4,693.71 |
Price/Book Value | 2.02 |
Price/Sales | 0.67 |
Price/Cash Flow | — |
Price/Earnings
MYGN
Financial Strength
Metric | MYGN |
|---|---|
Quick Ratio | 1.55 |
Current Ratio | 1.98 |
Interest Coverage | −6.89 |
Quick Ratio
MYGN
Profitability
Metric | MYGN |
|---|---|
Return on Assets (Normalized) | −5.72% |
Return on Equity (Normalized) | −11.63% |
Return on Invested Capital (Normalized) | −4.48% |
Return on Assets
MYGN
Diagnostics & Research Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | LOCK|#%qQ$dL$ | LOCK|R$ | $266B | |||
| Danaher Corp DHR | LOCK|^>!%#?n | LOCK|W@# | $166B | |||
| IDEXX Laboratories Inc IDXX | LOCK|z>#HB^N | LOCK|p@ | $55B | |||
| Agilent Technologies Inc A | LOCK|mxp?CpK | LOCK|DF | $50B | |||
| Waters Corp WAT | LOCK|C!K&fH | LOCK|r& | $47B | |||
| IQVIA Holdings Inc IQV | LOCK|^X>H%% | LOCK|XhXc | $45B | |||
| Mettler-Toledo International Inc MTD | LOCK|@jR@nF^ | LOCK|dyP#t | $35B | |||
| Illumina Inc ILMN | LOCK|z$r#>c | LOCK|#bSY | $32B | |||
| Labcorp Holdings Inc LH | LOCK|?YSS&>J | LOCK|p^s#n | $30B | |||
| Quest Diagnostics Inc DGX | LOCK|L#z$><k | LOCK|X@fXm | $28B |
United States